FM Nirmala Sitharaman said the government will soon announce measures to deal with the impact of Coronavirus outbreak on the domestic industry

The central government has constituted a Task Force on active pharmaceutical ingredients (APIs) to formulate a road map for the enhanced production of generic drugs in India

Shortages and potential price increases of generic drugs from India loom if the coronavirus outbreak disrupts suppliers of pharmaceutical ingredients in China past April, according to industry experts. An important supplier of generic drugs to the world, Indian companies procure almost 70% of the active pharmaceutical ingredients (APIs) for their medicines from China; The IMF has said that India urgently needs more ambitious structural and financial sector reform measures and a medium-term fiscal consolidation strategy due to the rising debt levels while ensuring a more accommodative fiscal stance in the budget. International Monetary Fund (IMF) spokesperson Gerry Rice said the economic environment in India is weaker than what the organisation had forecast earlier. This and more news on News Blast.Also read: India's wholesale inflation rose to 8-month high of 3.1% in JanuaryAlso read: Page Industries share price falls 8% post Q3 earnings  

Urgent need for more ambitious structural, financial sector reforms in India: IMFThe IMF has said that India urgently needs more ambitious structural and financial sector reform measures and a medium-term fiscal consolidation strategy due to the rising debt levels while ensuring a more accommodative fiscal stance in the budget. International Monetary Fund (IMF) spokesperson Gerry Rice said the economic environment in India is weaker than what the organisation had forecast earlier....

Generic drugmakers say they currently have enough active pharmaceutical ingredients supplies from China to cover their operations for up to about three months

The deal comprises a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines

Most in the Indian pharma industry are hopeful that the new National List of Essential Medicines (NLEM) expected in 2020 will not be too disruptive

Arjun Deshpande's unique pharmacy chain Generic Aadhar sells generic medicines to the masses at much cheaper rates than the market price

According to the report 'India: the emerging hub for biologics and biosimilars', the Indian pharmaceutical companies have launched 123 biosimilars and currently have 201 active biosimilars covering multiple indications in the development pipeline

Diabetes drug price: Companies are talking of a significant price cut. Intas Pharmaceuticals, according to a senior official in the company, will hit the market today with two versions

Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Rajiv Malik, President, Mylan, speaks about the impact the deal will have on India operations, the challenges in generic drugs and the role that China will play

The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019

Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year

Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year

The collateral damage of the United States' trade wars is being felt around the world as President Donald Trump renegotiates relationships with many of Washington's top trading partners.

The communication also directed the state-level authorities to communicate to the DCGI at the earliest on the action initiated by them.

The super rich are pumping enormous amounts of money into research that will extend life - and keep death at bay for a long, long time...